InvestorsHub Logo
Followers 44
Posts 14699
Boards Moderated 0
Alias Born 09/16/2012

Re: DNORWOOD post# 7542

Tuesday, 03/19/2024 11:32:45 AM

Tuesday, March 19, 2024 11:32:45 AM

Post# of 7587
Nah. Maybe to $3 for a little bit. This is exactly what's to be expected upon imminent approval. I have no issues with a raise like this. Plus Geron's now a takeover target so the cash will be reflected in the purchase price.

>>The gross proceeds to Geron from this underwritten offering, before deducting the underwriting discount and other estimated offering expenses, are expected to be approximately $150.0 million. Geron currently intends to use the net proceeds from this offering, together with its existing cash, cash equivalents, and current and noncurrent marketable securities, to fund the potential commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the U.S, and potential launch and commercialization of imetelstat in low or intermediate-1 risk myelodysplastic syndromes in the EU, subject to receipt of regulatory approvals, as well as continued development and potential regulatory submissions for imetelstat in relapsed/refractory myelofibrosis. Geron intends to use the remaining proceeds, if any, for working capital and general corporate purposes.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GERN News